Table 1. Patent’s baseline clinical characteristics.
| Variable | Non-intubated VATS (n=30) | Intubated VATS (n=30) | P value |
|---|---|---|---|
| Age | 64.9±10.5 | 66.1±9.5 | 0.654 |
| Sex | |||
| Male | 10 (33.3%) | 12 (40.0%) | |
| Female | 20 (66.7%) | 18 (60.0%) | 0.592 |
| BMI | 23.8±3.2 | 23.5±2.9 | 0.634 |
| Smoking history | |||
| Smoker | 7 (23.3%) | 9 (30.0%) | 0.559 |
| Non-smoker | 23 (76.7%) | 21 (70.0%) | |
| FEV1 | 94.8±9.3 | 95.1±16.8 | 0.948 |
| DLOC | 88.9±17.9 | 91.1±27.3 | 0.711 |
| Lobe % | |||
| RUL | 8 (26.7%) | 11 (36.7%) | |
| RML | 5 (16.7%) | 5 (16.7%) | |
| RLL | 6 (20.0%) | 4 (13.3%) | 0.861 |
| LUL | 8 (26.7%) | 6 (20.0%) | |
| LLL | 3 (10.0%) | 4 (13.3%) | |
| Cell type % | |||
| Adenocarcinoma | 26 (86.7%) | 25 (83.3%) | |
| Squamous cell carcinoma | 4 (13.3%) | 4 (13.3%) | 0.601 |
| Adenosquamous cell carcinoma | 0 | 1 (3.3%) |
VATS, video-assisted thoracoscopic surgery.